



(51) International Patent Classification:

C07D 243/24 (2006.01) **A61P 21/00** (2006.01)
C07D 401/12 (2006.01) **C07D 409/12** (2006.01)
C07D 401/06 (2006.01) **C07D 413/04** (2006.01)
C07D 401/14 (2006.01) **C07D 413/12** (2006.01)
C07D 403/04 (2006.01) **C07D 413/14** (2006.01)
C07D 403/06 (2006.01) **C07D 417/04** (2006.01)
C07D 403/10 (2006.01) **C07D 417/12** (2006.01)
C07D 403/12 (2006.01) **C07D 471/04** (2006.01)
C07D 403/14 (2006.01) **C07D 471/10** (2006.01)
C07D 405/06 (2006.01) **C07D 487/04** (2006.01)
C07D 405/12 (2006.01) **C07D 498/04** (2006.01)
C07D 405/14 (2006.01) **A61K 31/5513** (2006.01)

(21) International Application Number:

PCT/US2021/058260

(22) International Filing Date:

05 November 2021 (05.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/110,776 06 November 2020 (06.11.2020) US

(71) Applicant: **CYTOKINETICS, INC.** [US/US]; 280 East Grand Avenue, South San Francisco, California 94080 (US).

(72) Inventors: **MORGAN, Bradley P.**; c/o Cytokinetics, Inc., 280 East Grand Avenue, South San Francisco, California 94080 (US). **EVANS, Chris**; c/o Cytokinetics, Inc., 280 East Grand Avenue, South San Francisco, California 94080 (US). **LU, Pu-Ping**; c/o Cytokinetics, Inc., 280 East Grand Avenue, South San Francisco, California 94080 (US). **YAMASAKI, Makoto**; c/o Cytokinetics, Inc., 280 East Grand Avenue, South San Francisco, California 94080 (US). **WANG, Wenyue**; c/o Cytokinetics, Inc., 280 East Grand Avenue, South San Francisco, California 94080 (US). **COLLIBEE, Scott**; c/o Cytokinetics, Inc., 280 East Grand Avenue, South San Francisco, California 94080 (US). **MAKINO, Takuya**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-


ku, Tokyo 103-8411 (JP). **TSUCHIYA, Kazuyuki**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **KUROSAKI, Toshio**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **YAMAKI, Susumu**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **HONJO, Eriko**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **KOIZUMI, Yuka**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **KATOH, Naoto**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **SEKIOKA, Ryuichi**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **KURIWAKI, Ikumi**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **ANDERSEN, Denise**; c/o Cytokinetics, Inc., 280 East Grand Avenue, South San Francisco, California 94080 (US).

(74) Agent: **SILVERMAN, Lisa** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF



(57) Abstract: Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X¹, X², R⁵, R⁶, R¹, R², R³, and R⁴ are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*